| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A dynamic model of quality competition with endogenous prices |
0 |
0 |
0 |
12 |
0 |
2 |
2 |
76 |
| Access regulation and cross-border mergers: Is international coordination beneficial? |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
46 |
| Access regulation and cross-border mergers: Is international coordination beneficial? |
0 |
0 |
0 |
61 |
0 |
0 |
0 |
218 |
| Are cooperatives more productive than investor-owned firms? Cross-industry evidence from Portugal |
0 |
0 |
2 |
68 |
0 |
0 |
4 |
98 |
| Bilateral monopolies and location choice |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
73 |
| Can Competition Reduce Quality? |
0 |
0 |
0 |
47 |
0 |
0 |
2 |
291 |
| Can Deunionization Lead to International Outsourcing? |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
112 |
| Can Deunionization Lead to International Outsourcing? |
0 |
0 |
0 |
133 |
0 |
0 |
0 |
514 |
| Can competition reduce quality? |
0 |
0 |
1 |
38 |
0 |
0 |
2 |
80 |
| Can competition reduce quality? |
0 |
0 |
1 |
108 |
0 |
0 |
1 |
303 |
| Can competition reduce quality? |
0 |
0 |
1 |
123 |
0 |
2 |
3 |
192 |
| Can deunionization lead to international outsourcing? |
0 |
0 |
0 |
4 |
0 |
0 |
1 |
83 |
| Can deunionization lead to international outsourcing? |
0 |
0 |
0 |
5 |
0 |
0 |
0 |
86 |
| Competing with precision: incentives for developing predictive biomarker tests |
0 |
0 |
0 |
27 |
0 |
0 |
1 |
10 |
| Competing with precision: incentives for developing predictive biomarker tests |
0 |
0 |
0 |
14 |
0 |
0 |
2 |
14 |
| Competition and Equity in Health Care Markets |
0 |
0 |
0 |
57 |
1 |
4 |
4 |
153 |
| Competition and Physician Behaviour: Does the Competitive Environment Affect the Propensity to Issue Sickness Certificates? |
0 |
0 |
0 |
11 |
0 |
0 |
1 |
41 |
| Competition and Quality in Regulated Markets with Sluggish Demand |
0 |
0 |
0 |
45 |
0 |
0 |
0 |
205 |
| Competition and Quality in Regulated Markets: a Differential-Game Approach |
0 |
0 |
0 |
82 |
0 |
0 |
1 |
382 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
143 |
1 |
1 |
1 |
576 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
108 |
0 |
0 |
2 |
408 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
84 |
0 |
0 |
0 |
418 |
| Competition and physician behaviour: Does the competitive environment the propensity to issue sickness certificates? |
0 |
0 |
0 |
70 |
0 |
0 |
1 |
77 |
| Competition and quality in regulated markets with sluggish demand |
0 |
0 |
0 |
44 |
0 |
0 |
1 |
179 |
| Competition and quality in regulated markets: a differential-game approach |
0 |
0 |
0 |
88 |
0 |
0 |
1 |
243 |
| Competition and quality in regulated markets: a differential-game approach |
0 |
0 |
0 |
149 |
0 |
0 |
0 |
486 |
| Competition, quality and integrated health care |
0 |
2 |
4 |
67 |
0 |
2 |
8 |
75 |
| Cross border mergers and strategic trade policy with two-part taxation: is international policy coordination beneficial? |
0 |
0 |
0 |
23 |
0 |
0 |
4 |
139 |
| Do Hospital Mergers Reduce Waiting Times? Theory and Evidence from the English NHS |
0 |
0 |
0 |
12 |
0 |
0 |
4 |
21 |
| Do Hospital Mergers Reduce Waiting Times? Theory and Evidence from the English NHS |
0 |
0 |
0 |
0 |
1 |
1 |
5 |
8 |
| Do Hospital Mergers Reduce Waiting Times? Theory and Evidence from the English NHS |
0 |
0 |
0 |
23 |
0 |
1 |
5 |
18 |
| Do Treatment Decisions Depend on Physicians` Financial Incentives? |
0 |
0 |
0 |
36 |
0 |
0 |
0 |
50 |
| Do Treatment Decisions Depend on Physicians’ Financial Incentives? |
0 |
0 |
1 |
10 |
0 |
1 |
4 |
65 |
| Do hospital mergers reduce waiting times? Theory and evidence from the english NHS |
0 |
0 |
2 |
30 |
0 |
3 |
9 |
21 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
0 |
0 |
18 |
0 |
0 |
1 |
85 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
0 |
1 |
22 |
0 |
1 |
2 |
13 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
0 |
0 |
72 |
0 |
1 |
1 |
151 |
| Does Remote Work Improve or Impair Firm Labour Productivity? Longitudinal Evidence from Portugal |
0 |
0 |
5 |
149 |
0 |
1 |
14 |
373 |
| Does monetary punishment crowd out pro-social motivation? The case of hospital bed-blocking |
0 |
0 |
0 |
79 |
1 |
1 |
1 |
439 |
| Does remote work improve or impair firm labour productivity? Longitudinal evidence from |
0 |
2 |
5 |
392 |
1 |
12 |
34 |
1,309 |
| Downstream Merger with Oligopolistic Input Suppliers |
0 |
0 |
0 |
94 |
0 |
0 |
4 |
542 |
| Downstream merger with oligopolistic input suppliers |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
89 |
| Dynamic Hospital Competition Under Rationing by Waiting Times |
0 |
0 |
0 |
29 |
0 |
0 |
0 |
65 |
| Dynamic hospital competition under rationing by waiting times |
0 |
0 |
0 |
48 |
0 |
0 |
0 |
83 |
| Economic integration and environmental policy coordination |
0 |
0 |
0 |
9 |
0 |
1 |
3 |
49 |
| Employment Protection versus Flexicurity: On Technology Adoption in Unionised Firms |
0 |
0 |
0 |
81 |
0 |
0 |
0 |
258 |
| Employment protection and unemployment benefits: On technology adoption and job creation in a matching model |
0 |
0 |
0 |
66 |
0 |
1 |
1 |
187 |
| Employment protection and unemployment benefits: On technology adoption and job creation in a matching model |
0 |
0 |
0 |
94 |
0 |
0 |
0 |
63 |
| Employment protection and unemployment benefits: on technology adoption and job creation in a matching model |
0 |
0 |
0 |
22 |
0 |
1 |
1 |
94 |
| Employment protection versus flexicurity: on technology adoption in unionised firms |
0 |
0 |
0 |
32 |
0 |
0 |
1 |
128 |
| Firm Heterogeneity and Wages in Unionised Labour Markets: Theory and Evidence |
0 |
0 |
0 |
30 |
0 |
0 |
3 |
111 |
| Firm Ownership and Rent Sharing |
0 |
0 |
0 |
19 |
0 |
0 |
1 |
94 |
| Firm heterogeneity and wages in unionised labour markets: Theory and evidence |
0 |
0 |
0 |
69 |
0 |
1 |
1 |
198 |
| Firm ownership and rent sharing |
0 |
0 |
0 |
16 |
0 |
0 |
1 |
97 |
| Foreign acquisition and internal organization |
0 |
0 |
0 |
29 |
0 |
0 |
1 |
103 |
| Foreign acquisition and internal organization |
0 |
0 |
0 |
67 |
0 |
1 |
3 |
143 |
| Gatekeeping In Health Care |
0 |
0 |
0 |
148 |
0 |
0 |
1 |
603 |
| Gatekeeping in Health Care |
0 |
0 |
0 |
252 |
0 |
0 |
1 |
1,809 |
| Globalisation And Union Opposition To Technological Change |
0 |
0 |
0 |
80 |
0 |
0 |
1 |
240 |
| Globalisation and union opposition to technological change |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
86 |
| Globalisation and union opposition to technological change |
0 |
0 |
1 |
5 |
0 |
0 |
1 |
95 |
| Globalization and Union Opposition to Technological Change |
0 |
0 |
0 |
143 |
0 |
0 |
1 |
976 |
| Globalization, Product Differentiation and Wage Inequality |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
30 |
| Globalization, Product Differentiation and Wage Inequality |
0 |
0 |
0 |
70 |
0 |
1 |
3 |
187 |
| Globalization, product differentiation and wage inequality |
0 |
0 |
1 |
60 |
0 |
0 |
3 |
207 |
| Globalization, product differentiation and wage inequality |
0 |
0 |
0 |
74 |
0 |
1 |
2 |
355 |
| Good Jobs, Bad Jobs and Redistribution |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
644 |
| Good Jobs, Bad Jobs and Redistribution |
0 |
0 |
0 |
39 |
0 |
0 |
0 |
271 |
| Good jobs, bad jobs and redistribution |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
76 |
| Good jobs, bad jobs and redistribution |
0 |
0 |
0 |
44 |
0 |
0 |
0 |
316 |
| Horizontal Mergers and Product Quality |
0 |
0 |
1 |
33 |
0 |
0 |
1 |
128 |
| Horizontal Mergers and Product Quality |
0 |
0 |
0 |
28 |
0 |
0 |
0 |
61 |
| Horizontal Mergers and Product Quality |
0 |
0 |
0 |
35 |
0 |
0 |
0 |
109 |
| Horizontal Mergers and Product Quality- |
0 |
0 |
1 |
60 |
0 |
0 |
6 |
141 |
| Hospital Competition and Quality with Regulated Prices |
0 |
0 |
0 |
306 |
0 |
1 |
2 |
1,108 |
| Hospital Competition in the National Health Service: Evidence from a Patient Choice Reform |
0 |
0 |
0 |
70 |
0 |
0 |
2 |
139 |
| Hospital Competition in the National Health Service: Evidence from a Patient Choice Reform |
0 |
0 |
1 |
31 |
0 |
0 |
4 |
60 |
| Hospital Competition under Pay-for-Performance: Quality, Mortality and Readmissions |
0 |
2 |
2 |
101 |
1 |
3 |
5 |
131 |
| Hospital Competition under Pay-for-Performance: Quality, Mortality and Readmissions |
0 |
2 |
2 |
35 |
0 |
4 |
5 |
191 |
| Hospital Competition with Soft Budgets |
0 |
0 |
0 |
48 |
0 |
0 |
0 |
192 |
| Hospital Mergers with Regulated Prices |
0 |
0 |
1 |
90 |
0 |
0 |
3 |
138 |
| Hospital Mergers: A Spatial Competition Approach |
0 |
0 |
0 |
121 |
0 |
0 |
1 |
115 |
| Hospital Mergers: A Spatial Competition Approach |
0 |
0 |
0 |
37 |
0 |
0 |
1 |
125 |
| Hospital competition and quality with regulated prices |
0 |
0 |
0 |
149 |
0 |
0 |
2 |
384 |
| Hospital competition when patients learn through experience |
0 |
0 |
0 |
27 |
0 |
2 |
5 |
9 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
31 |
0 |
0 |
0 |
61 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
74 |
0 |
0 |
1 |
150 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
46 |
0 |
0 |
0 |
123 |
| How does the type of remuneration affect physician behaviour? Fixed salary versus fee-for-service |
0 |
0 |
2 |
70 |
0 |
0 |
7 |
140 |
| Industry Concentration and Strategic Trade Policy in Successive Oligopoly |
0 |
0 |
0 |
161 |
0 |
0 |
0 |
629 |
| Industry concentration and strategic trade policy in successive oligopoly |
0 |
0 |
0 |
13 |
0 |
0 |
1 |
68 |
| International mergers and trade liberalisation: Implications for unionised |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
349 |
| International outsourcing and trade union (de-)centralisation |
0 |
0 |
0 |
17 |
0 |
1 |
1 |
49 |
| Investment and Quality Competition in Healthcare Markets |
0 |
0 |
1 |
30 |
1 |
1 |
3 |
66 |
| Management, Performance And Pay |
0 |
1 |
8 |
22 |
0 |
1 |
9 |
21 |
| Managerial delegation and merger incentives |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
31 |
| Margins and Market Shares: Pharmacy Incentives for Generic Substitution |
0 |
0 |
1 |
34 |
0 |
0 |
2 |
201 |
| Margins and Market Shares: Pharmacy Incentives for Generic Substitution |
0 |
0 |
2 |
114 |
0 |
0 |
2 |
121 |
| Margins and Market Shares:Pharmacy Incentives for Generic Substitution |
0 |
0 |
0 |
91 |
0 |
0 |
0 |
224 |
| Merger Profitability in Unionized Oligopoly |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
340 |
| Merger Profitability in Unionized Oligopoly |
0 |
0 |
0 |
7 |
0 |
0 |
0 |
33 |
| Merger Profitability in Unionized Oligopoly |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
508 |
| Merger Profitability in Unionized Oligopoly |
0 |
0 |
0 |
95 |
1 |
1 |
2 |
407 |
| Merger control in retail markets with national pricing |
0 |
0 |
0 |
27 |
0 |
0 |
1 |
12 |
| Merger, partial collusion and relocation |
0 |
0 |
0 |
162 |
0 |
0 |
0 |
492 |
| Merger, partial collusion and relocation |
0 |
1 |
1 |
3 |
0 |
6 |
6 |
52 |
| Mergers and capital flight in unionised oligopolies: Is there scope for a 'national champion' policy? |
0 |
0 |
0 |
50 |
0 |
0 |
0 |
160 |
| Mergers and capital flight in unionised oligopolies: Is there scope for a 'national champion' policy? |
0 |
0 |
0 |
7 |
0 |
1 |
1 |
94 |
| Mommy tracks and public policy: On self-fulfilling prophecies and gender gaps in promotion |
0 |
0 |
0 |
35 |
0 |
0 |
4 |
157 |
| National pricing with local quality competition |
0 |
0 |
1 |
9 |
0 |
1 |
2 |
20 |
| National pricing with local quality competition |
0 |
0 |
0 |
24 |
0 |
0 |
1 |
60 |
| National versus International Mergers in Unionised Oligopoly |
0 |
0 |
0 |
132 |
0 |
0 |
0 |
507 |
| National versus international mergers in unionised oligopoly |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
94 |
| North-South Technology Transfer in Unionised Multinationals |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
121 |
| North-South technology transfer in unionised multinationals |
0 |
0 |
0 |
14 |
0 |
0 |
0 |
77 |
| North-South technology transfer in unionised multinationals |
0 |
0 |
0 |
39 |
0 |
0 |
1 |
121 |
| North-South technology transfer in unionised multinationals |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
156 |
| Optimal dynamic volume-based price regulation |
0 |
0 |
0 |
45 |
0 |
0 |
2 |
68 |
| Outsourcing in Contests |
0 |
0 |
0 |
90 |
0 |
0 |
1 |
325 |
| Outsourcing in Contests |
0 |
0 |
0 |
16 |
0 |
0 |
0 |
77 |
| Patents: Incentives for R&D or Marketing? |
0 |
0 |
0 |
9 |
0 |
0 |
0 |
49 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
0 |
53 |
0 |
0 |
6 |
119 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
0 |
42 |
0 |
0 |
0 |
120 |
| Patient Mobility, Health Care Quality and Welfare |
1 |
1 |
1 |
51 |
3 |
3 |
3 |
152 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
1 |
45 |
0 |
0 |
1 |
162 |
| Patient mobility and health care quality when regions and patients differ in income |
0 |
0 |
0 |
13 |
0 |
1 |
2 |
66 |
| Pharmaceutical Patents: Incentives for R&D or Marketing? |
0 |
0 |
1 |
275 |
0 |
0 |
1 |
1,088 |
| Preschool Education in Brazil: Does Public Supply Crowd Out Private Enrollment? |
0 |
0 |
0 |
2 |
0 |
0 |
1 |
15 |
| Preschool Education in Brazil: Does Public Supply Crowd Out Private Enrollment? |
0 |
0 |
0 |
47 |
0 |
0 |
0 |
73 |
| Preschool education in Brazil: does public supply crowd out private enrollment ? |
0 |
0 |
0 |
21 |
0 |
0 |
1 |
48 |
| Preschool education in Brazil:Does public supply crowd out private enrollment? |
0 |
0 |
0 |
176 |
2 |
4 |
14 |
104 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
0 |
13 |
0 |
0 |
3 |
114 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
2 |
100 |
0 |
0 |
3 |
118 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
2 |
95 |
0 |
0 |
7 |
143 |
| Price and quality in spatial competition |
0 |
0 |
2 |
94 |
0 |
0 |
4 |
225 |
| Price and quality in spatial competition |
0 |
0 |
1 |
162 |
0 |
0 |
1 |
248 |
| Privatization and corporate restructuring |
0 |
0 |
0 |
35 |
0 |
0 |
0 |
142 |
| Quality and location choices under price regulation |
0 |
0 |
0 |
25 |
0 |
0 |
1 |
105 |
| Quality and location choices under price regulation |
0 |
0 |
0 |
21 |
0 |
0 |
1 |
107 |
| Quality competition with motivated providers and sluggish demand |
0 |
0 |
0 |
8 |
0 |
0 |
1 |
135 |
| Quality competition with motivated providers and sluggish demand |
0 |
0 |
0 |
59 |
0 |
0 |
1 |
124 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
0 |
44 |
0 |
0 |
2 |
145 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
3 |
108 |
0 |
0 |
4 |
202 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
0 |
83 |
0 |
0 |
1 |
117 |
| Quality discrimination in healthcare markets |
0 |
1 |
1 |
23 |
0 |
1 |
4 |
13 |
| Quality provision in hospital markets with demand inertia:The role of patient expectations |
0 |
0 |
0 |
24 |
0 |
1 |
1 |
55 |
| Rain, agriculture, and tariffs |
0 |
0 |
0 |
30 |
0 |
0 |
0 |
68 |
| Rain, food and tariffs |
0 |
0 |
0 |
19 |
0 |
0 |
1 |
85 |
| Reference Pricing of Pharmaceuticals |
0 |
0 |
0 |
20 |
0 |
0 |
0 |
121 |
| Reference Pricing of Pharmaceuticals |
0 |
0 |
0 |
269 |
0 |
0 |
0 |
930 |
| Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment |
0 |
0 |
0 |
103 |
0 |
0 |
1 |
385 |
| Reference pricing with endogenous generic entry |
0 |
0 |
1 |
16 |
0 |
0 |
4 |
75 |
| Reference pricing with endogenous generic entry |
0 |
0 |
0 |
52 |
0 |
0 |
0 |
90 |
| Regulation, generic competition and pharmaceutical prices: Theory and evidence from a natural experiment |
0 |
2 |
4 |
149 |
0 |
2 |
5 |
487 |
| Rent-Seeking in a Unionised Monopoly |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
321 |
| Restructuring in privatised firms: a Statis approach |
0 |
0 |
0 |
19 |
0 |
0 |
0 |
116 |
| Restructuring in privatised firms:a Statis approach |
0 |
0 |
0 |
4 |
0 |
0 |
1 |
124 |
| Socioeconomic Status and PhysiciansíTreatment Decisions |
0 |
0 |
0 |
19 |
0 |
0 |
1 |
58 |
| Socioeconomic Status and Physicians’ Treatment Decisions |
0 |
0 |
0 |
10 |
0 |
0 |
2 |
69 |
| Taking the competitor´s pill: when combination therapies enter pharmaceutical markets |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
4 |
| Taking the competitor’s pill: when combination therapies enter pharmaceutical markets |
0 |
0 |
12 |
12 |
0 |
0 |
21 |
21 |
| Technology resistance and globalisation with trade unions: the choice between employment protection and flexicurity |
0 |
0 |
0 |
122 |
0 |
1 |
1 |
485 |
| Technology resistance and globalisation with trade unions: the choice between employment protection and flexicurity |
0 |
0 |
0 |
16 |
0 |
2 |
2 |
162 |
| The Division of Revenues from Unexpected Demand Shocks |
0 |
2 |
2 |
2 |
0 |
5 |
5 |
5 |
| The Division of Unexpected Revenue Shocks |
0 |
0 |
0 |
22 |
0 |
0 |
3 |
37 |
| The effect of private versus public ownership on labour earnings |
0 |
0 |
1 |
27 |
0 |
0 |
3 |
108 |
| The price of cost-effectiveness thresholds |
0 |
0 |
0 |
24 |
0 |
0 |
1 |
11 |
| The price of cost-effectiveness thresholds |
0 |
1 |
2 |
26 |
0 |
1 |
3 |
14 |
| Trade, renewable energy, and market power in power markets |
0 |
0 |
15 |
15 |
0 |
0 |
32 |
32 |
| Union Collusion and Intra-Industry Trade |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
675 |
| Total Working Papers |
1 |
17 |
100 |
9,435 |
13 |
84 |
395 |
33,947 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A dynamic model of quality competition with endogenous prices |
0 |
1 |
3 |
26 |
0 |
2 |
6 |
109 |
| ARE COOPERATIVES MORE PRODUCTIVE THAN INVESTOR-OWNED FIRMS? CROSS-INDUSTRY EVIDENCE FROM PORTUGAL |
0 |
0 |
0 |
26 |
2 |
3 |
11 |
191 |
| Bilateral monopolies and location choice |
0 |
0 |
0 |
47 |
0 |
1 |
1 |
176 |
| Can Competition Reduce Quality? |
0 |
0 |
0 |
33 |
0 |
1 |
1 |
174 |
| Can deunionization lead to international outsourcing? |
0 |
0 |
0 |
74 |
0 |
0 |
0 |
292 |
| Company Taxation and Merger Incentives in International Oligopoly: on International Policy Coordination with Strategic Trade |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
98 |
| Competing with precision: incentives for developing predictive biomarker tests |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
2 |
| Competition and equity in health care markets |
0 |
0 |
1 |
21 |
0 |
0 |
1 |
87 |
| Competition and physician behaviour: Does the competitive environment affect the propensity to issue sickness certificates? |
0 |
1 |
1 |
3 |
0 |
1 |
2 |
24 |
| Competition and quality in health care markets: A differential-game approach |
0 |
0 |
0 |
48 |
0 |
0 |
1 |
230 |
| Competition and waiting times in hospital markets |
0 |
0 |
1 |
132 |
0 |
0 |
2 |
502 |
| Competition in Regulated Markets with Sluggish Beliefs about Quality |
0 |
0 |
0 |
18 |
0 |
0 |
3 |
76 |
| Competition policy for health care provision in Norway |
0 |
0 |
0 |
5 |
0 |
0 |
1 |
36 |
| Competition, quality and integrated health care |
0 |
1 |
4 |
4 |
0 |
4 |
10 |
10 |
| Do treatment decisions depend on physicians' financial incentives? |
1 |
2 |
4 |
38 |
1 |
6 |
12 |
150 |
| Does monetary punishment crowd out pro-social motivation? A natural experiment on hospital length of stay |
0 |
0 |
0 |
54 |
0 |
0 |
3 |
184 |
| Downstream merger with upstream market power |
0 |
0 |
0 |
114 |
0 |
0 |
0 |
520 |
| Dynamic hospital competition under rationing by waiting times |
0 |
0 |
1 |
8 |
0 |
0 |
1 |
30 |
| Editorial note |
0 |
0 |
0 |
8 |
0 |
0 |
0 |
41 |
| Employment Protection Versus Flexicurity: On Technology Adoption in Unionised Firms |
0 |
0 |
0 |
20 |
0 |
0 |
1 |
88 |
| Employment Protection and Unemployment Benefits: On Technology Adoption and Job Creation in a Matching Model |
0 |
0 |
0 |
9 |
0 |
0 |
1 |
65 |
| Firm Ownership and Rent Sharing |
0 |
0 |
1 |
9 |
0 |
0 |
3 |
75 |
| Firm heterogeneity and wages in unionised labour markets: Theory and evidence |
0 |
0 |
0 |
37 |
0 |
0 |
3 |
145 |
| Foreign acquisition and internal organization |
2 |
2 |
7 |
28 |
3 |
3 |
18 |
135 |
| Gatekeeping in health care |
0 |
0 |
0 |
170 |
0 |
0 |
2 |
735 |
| Globalisation and union opposition to technological change |
0 |
0 |
1 |
94 |
0 |
0 |
2 |
372 |
| Globalization, product differentiation, and wage inequality |
0 |
0 |
1 |
3 |
1 |
1 |
3 |
23 |
| Globalization, product differentiation, and wage inequality |
0 |
0 |
0 |
35 |
0 |
0 |
0 |
185 |
| Good Jobs, Bad Jobs and Redistribution* |
0 |
0 |
0 |
44 |
0 |
0 |
1 |
288 |
| Horizontal mergers and product quality |
0 |
0 |
0 |
2 |
1 |
1 |
3 |
32 |
| Horizontal mergers and product quality |
0 |
0 |
1 |
8 |
0 |
0 |
3 |
53 |
| Hospital Competition and Quality with Regulated Prices |
0 |
0 |
1 |
58 |
2 |
3 |
10 |
193 |
| Hospital Competition with Soft Budgets |
0 |
0 |
0 |
9 |
1 |
1 |
2 |
62 |
| Hospital Mergers with Regulated Prices |
0 |
0 |
0 |
5 |
0 |
0 |
2 |
57 |
| Hospital competition in a national health service: Evidence from a patient choice reform |
0 |
0 |
1 |
5 |
2 |
2 |
5 |
24 |
| Hospital competition under pay‐for‐performance: Quality, mortality, and readmissions |
1 |
1 |
3 |
8 |
2 |
3 |
10 |
59 |
| Hospital competition when patients learn through experience |
0 |
0 |
0 |
0 |
2 |
4 |
4 |
4 |
| How Does The Type of Remuneration Affect Physician Behavior? |
0 |
2 |
3 |
30 |
0 |
4 |
12 |
81 |
| Industry Concentration and Strategic Trade Policy in Successive Oligopoly |
0 |
0 |
0 |
31 |
0 |
0 |
0 |
128 |
| International mergers and trade liberalisation: implications for unionised labour |
0 |
0 |
0 |
41 |
0 |
1 |
1 |
195 |
| International outsourcing and trade union (de-)centralisation |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
9 |
| Investment and quality competition in healthcare markets |
0 |
0 |
2 |
3 |
0 |
1 |
4 |
18 |
| Management Practices, Pay, and Pay Inequality |
0 |
0 |
1 |
1 |
0 |
2 |
3 |
3 |
| Managerial Delegation and Merger Incentives with Asymmetric Costs |
0 |
0 |
0 |
79 |
0 |
0 |
1 |
262 |
| Margins and market shares: Pharmacy incentives for generic substitution |
0 |
0 |
2 |
55 |
0 |
0 |
4 |
316 |
| Merger, Partial Collusion and Relocation |
0 |
0 |
0 |
6 |
0 |
1 |
1 |
58 |
| Mergers and capital flight in unionised oligopolies: Is there scope for a "national champion" policy? |
0 |
0 |
0 |
19 |
0 |
1 |
1 |
89 |
| Mommy tracks and public policy: On self-fulfilling prophecies and gender gaps in hiring and promotion |
1 |
2 |
9 |
55 |
1 |
2 |
14 |
175 |
| National pricing with local quality competition |
0 |
0 |
1 |
2 |
0 |
0 |
1 |
5 |
| National versus international mergers in unionized oligopoly |
0 |
0 |
0 |
17 |
0 |
0 |
0 |
75 |
| North–South technology transfer in unionised multinationals |
0 |
0 |
0 |
25 |
0 |
0 |
0 |
151 |
| Optimal dynamic volume-based price regulation |
0 |
0 |
0 |
4 |
0 |
1 |
3 |
23 |
| Optimal funding coverage in a mixed oligopoly with quality competition and price regulation |
0 |
0 |
1 |
8 |
0 |
2 |
4 |
17 |
| Outsourcing in contests |
0 |
1 |
1 |
46 |
0 |
1 |
3 |
231 |
| Patient mobility and health care quality when regions and patients differ in income |
0 |
0 |
1 |
17 |
0 |
0 |
2 |
75 |
| Patient mobility, health care quality and welfare |
0 |
0 |
0 |
21 |
1 |
1 |
8 |
98 |
| Paying for pharmaceuticals: uniform pricing versus two-part tariffs |
0 |
0 |
0 |
3 |
0 |
1 |
2 |
19 |
| Pharmaceutical Patents: Incentives for Research and Development or Marketing? |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
| Preschool Education in Brazil: Does Public Supply Crowd Out Private Enrollment? |
0 |
0 |
1 |
9 |
0 |
0 |
3 |
82 |
| Price and quality in spatial competition |
0 |
0 |
3 |
57 |
1 |
1 |
8 |
240 |
| Price regulation and parallel imports of pharmaceuticals |
1 |
1 |
1 |
24 |
1 |
3 |
4 |
110 |
| Product Market Integration and Environmental Policy Coordination in An International Duopoly |
0 |
0 |
0 |
47 |
0 |
0 |
1 |
172 |
| Quality and Location Choices under Price Regulation |
0 |
1 |
1 |
169 |
0 |
3 |
6 |
495 |
| Quality competition with motivated providers and sluggish demand |
0 |
0 |
0 |
12 |
0 |
0 |
1 |
126 |
| Quality competition with profit constraints |
0 |
0 |
0 |
32 |
3 |
4 |
8 |
160 |
| Quality provision in hospital markets with demand inertia: The role of patient expectations |
0 |
0 |
0 |
3 |
0 |
0 |
0 |
8 |
| Rain, agriculture, and tariffs |
0 |
0 |
1 |
39 |
2 |
2 |
6 |
163 |
| Reference pricing of pharmaceuticals |
0 |
1 |
1 |
97 |
0 |
1 |
1 |
257 |
| Reference pricing with endogenous generic entry |
0 |
0 |
1 |
12 |
0 |
0 |
1 |
56 |
| Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment |
0 |
0 |
0 |
73 |
0 |
1 |
1 |
248 |
| Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment |
0 |
0 |
1 |
75 |
0 |
0 |
3 |
334 |
| Rent-seeking in a unionised monopoly |
0 |
0 |
0 |
29 |
0 |
0 |
1 |
188 |
| Restructuring in privatised firms: A Statis approach |
0 |
0 |
1 |
14 |
0 |
0 |
1 |
73 |
| Socio‐economic status and physicians' treatment decisions |
0 |
0 |
0 |
6 |
1 |
1 |
2 |
32 |
| The effect of private versus public ownership on labour earnings |
0 |
0 |
0 |
4 |
0 |
0 |
1 |
49 |
| The impact of private vs. public ownership on the level and structure of employment |
0 |
0 |
0 |
5 |
0 |
1 |
1 |
34 |
| The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets |
0 |
0 |
3 |
4 |
1 |
2 |
12 |
13 |
| Therapeutic reference pricing and drug innovation incentives |
0 |
0 |
0 |
0 |
1 |
2 |
5 |
14 |
| Union collusion and intra-industry trade |
0 |
0 |
0 |
27 |
0 |
0 |
0 |
154 |
| When does remote electronic access (not) boost productivity? Longitudinal evidence from Portugal |
0 |
0 |
1 |
10 |
0 |
0 |
1 |
27 |
| Total Journal Articles |
6 |
16 |
67 |
2,433 |
30 |
76 |
262 |
10,592 |
LogEc is hosted by the
Örebro University School of Business.